Two recent studies investigated the connections between cannabis use and developing certain heart conditions.
On November 6th, 2023, the American Heart Association (AHA) released results from two studies from different research groups on the risk of cannabis use and developing heart issues, particularly heart attack and heart failure (1). The two studies were poster abstracts to be presented in AHA’s Scientific Sessions meeting on November 11-13 (1).
In one study, researchers tracked 156,999 individuals for almost four years (1). At the start of the study, the individuals did not have heart failure, and by the end of the study, an analysis stated that compared to those who never used cannabis, individuals who used cannabis daily had a 34% increased risk of developing heart failure (1).
“Prior research shows links between marijuana use and cardiovascular disease like coronary artery disease, heart failure and atrial fibrillation, which is known to cause heart failure,” said lead study author Yakubu Bene-Alhasan, MD, MPH (1). “Marijuana use isn’t without its health concerns, and our study provides more data linking its use to cardiovascular conditions. Our results should encourage more researchers to study the use of marijuana to better understand its health implications, especially on cardiovascular risk.”
One limitation in this study, the AHA article stated, was that the method of cannabis ingestion was not specified in the study (1).
In a second study, researchers analyzed hospital inpatient data from 28,835 individuals age 65 and older who were split into two groups—those who used cannabis and those who did not—while excluding tobacco users (1). The analysis found that of the individuals who used cannabis and already had cardiovascular risk factors, 13.9% had a major heart or brain event while hospitalized, compared to those who did not use cannabis (1).
Two factors made this study distinct from previous ones. “Since 2015, cannabis use in the US has almost doubled, and it is increasing in older adults, therefore, understanding the potential increased cardiovascular risk from cannabis use is important,” said lead study author Avilash Mondal, MD (1). “What is unique about our study is that patients who were using tobacco were excluded because cannabis and tobacco are sometimes used together, therefore, we were able to specifically examine cannabis use and cardiovascular outcomes.”
One limitation of the study, the AHA article explained, was that because the data came from such a large database, possible coding errors and variances might have occurred (1).
Reference
Work Smarter, Not Harder: How ASTM Standards for Cannabinoids Improve Your Operations
December 3rd 2024ASTM Standards D8557-24 and D8556-24, provide unified guidelines for GMP (Good Manufacturing Practices) and QMS (Quality Management Systems) in cannabis operations. These standards enhance compliance, product safety, and operational consistency across the industry for the benefit of operators, consumers, and other stakeholders in the industry.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.